International Niemann–Pick Disease Alliance

Menu

Calporta Therapeutics is developing small molecule agonists of TRPML1 for Niemann-Pick C

  • 23.06.15
  • Filed under: Research

Calporta Therapeutics is developing small molecule agonists of TRPML1 for the treatment of Niemann-Pick C Disease (NPC) and other lysosomal storage diseases. Calporta’s approach is based on research from the lab of Haoxing Xu, Ph.D., at the University of Michigan.

Read more here

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...